WHO Issues Alert Over Critical Scarcity of Obesity Injections

Less than a tenth of people eligible to benefit from weight-loss injections such as Wegovy have access to them, warns the WHO as it releases its inaugural recommendations on the therapies.

Given more than one billion individuals worldwide now classified as obese, it is calling for broader and more equitable access to these injectable treatments.

According to forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.

"The latest guidelines recognises that excess weight is a lifelong illness that can be managed with thorough and ongoing support," stated its chief Tedros Adhanom Ghebreyesus.

Substantial prices, constrained manufacturing, and distribution challenges are key barriers to universal access to the jabs that can aid individuals in losing substantial body mass, says the body.

Skinny Jab Scarcity

Even in the present most favorable scenario, the production of GLP-1 therapies might only reach around 100 million people – under 10% of the global need, as stated by the WHO.

The recommendation encourages governments and firms to expand access, via strategies like licensing agreements.

Exclusive production rights on the active ingredient – the main ingredient of a leading brand – is due to expire in several nations in 2026.

The Way Weight-Loss Jabs Operate

These medications imitate a natural hormone to slow digestion, reduce hunger and boost feelings of fullness so individuals reduce food intake.

Individuals usually start to lose weight in the initial weeks of starting on the regular doses.

Studies points to patients may see weight return within a year of stopping the drug, as their normal appetite resume.

To be above a healthy weight elevates your risk for contracting health problems, such as type 2 diabetes, heart disease, brain attack, and certain cancers.

Obesity concerns individuals in all nations and was linked to 3.7 million deaths worldwide in 2024, as per the WHO.